 |
Institut de recherche en astrophysique et planétologie |  |
|
Institut de recherche en astrophysique et planétologie | |
| HAL : hal-00453280, version 1 |
| PubMed : 16478882 |
| DOI : 10.1182/blood-2005-11-4429 |
| Fiche détaillée |  Récupérer au format |
 |
| Blood 107, 12 (2006) 4636-42 |
|
|
|
|
| Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). |
|
|
| Christophe Fermé 1Nicolas Mounier 2 |
|
|
| (15/06/2006) |
|
|
|
| From 1989 to 1996, 533 eligible patients with stage IIIB/IV Hodgkin lymphoma (HL) were randomly assigned to receive 6 cycles of hybrid MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin [doxorubicin], bleomycin, vinblastine; n = 266) or ABVPP (doxorubicin, bleomycin, vinblastine, procarbazine, prednisone; n = 267). Patients in complete remission (CR) or partial response of at least 75% after 6 cycles received 2 cycles of consolidation chemotherapy (CT) (n = 208) or subtotal nodal irradiation (RT) (n = 210). A better survival probability was observed after ABVPP alone: the 10-year overall survival (OS) estimates were 90% for ABVPP x 8, 78% for MOPP/ABV x 8, 82% for MOPP/ABV with RT, and 77% for ABVPP x 6 with RT (P = .03); and the 10-year disease-free survival (DFS) estimates were 70%, 76%, 79%, and 76%, respectively (P = .09). The 10-year DFS estimates for patients treated with consolidation CT or RT were 73% and 78% (P = .07), and OS estimates were 84% and 79%, respectively (P = .29). These results showed that RT was not superior to consolidation CT after a doxorubicin-induced CR in patients with advanced HL. An analysis of competing risks identified age more than 45 years as a significant risk factor for death, relapse, and second cancers. Prospective evaluation of late adverse events may improve the management of patients with HL. |
|
|
|
|
|
|
|
|
|
|
|
| 1 : | Service d'hématologie |
|
|
|
Institut Gustave Roussy |
|
|
| 2 : | Service d'onco-hématologie |
|
|
|
CHU Nice – Hôpital l'Archet |
|
|
| 3 : | Service d'hématologie-oncologie adultes |
|
|
|
Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Saint-Louis – Université Paris VII - Paris Diderot |
|
|
| 4 : | Service d'Hématologie Clinique et thérapie cellulaire |
|
|
|
CHU Limoges |
|
|
| 5 : | Laboratoire d'hématologie |
|
|
|
CHU Limoges |
|
|
| 6 : | Faculté de Médecine |
|
|
|
Université de Limoges |
|
|
| 7 : | Physiologie moléculaire de la réponse immune et des lymphoproliférations (PMRIL) |
|
|
|
CNRS : UMR6101 – Université de Limoges – IFR145 GEIST |
|
|
| 8 : | Centre d'étude spatiale des rayonnements (CESR) |
|
|
|
CNRS : UMR5187 – Observatoire Midi-Pyrénées – INSU – Université Paul Sabatier [UPS] - Toulouse III |
|
|
|
|
|
|
|
|
|
| Domaine | : | Sciences du Vivant/Immunologie |
| hal-00453280, version 1 | |
| http://hal.archives-ouvertes.fr/hal-00453280 | |
| oai:hal.archives-ouvertes.fr:hal-00453280 | |
| Contributeur : Claire Carrion | |
| Soumis le : Jeudi 4 Février 2010, 11:38:37 | |
| Dernière modification le : Jeudi 4 Février 2010, 11:38:37 | |
